Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Yowie Group Limited

ABN

98 084 370 669


We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to Fully paid ordinary shares 1 be issued

- Number of +securities issued or 105,407 2 to be issued (if known) or maximum number which may be issued
- of Principal terms the 3 if options, +securities (e.g. exercise price and expiry date; if +securities, partly paid the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)



⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes – The Shares will rank equally in all respects with fully paid shares currently on issue.
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	\$0.20 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of listed options exercisable at \$0.20 each on or before 15 December 2015
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the</i> ⁺ <i>securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	27 November 2014
6с	Number of ⁺ securities issued without security holder approval under rule 7.1	Nil
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil

⁺ See chapter 19 for defined terms.

- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If ⁺securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

Number	+Class
147,085,271	Fully paid ordinary shares
21,113,004	20 cents options expiring 15 December 2015

Nil

105,407

N/A

N/A

3,937,790 978,527

3 August 2015

Rule 7.1

Rule 7.1A

+ See chapter 19 for defined terms.

Appendix 3B New issue announcement

		Number	+Class
9	Number and ⁺ class of all ⁺ securities not quoted on ASX	2,500,000	\$0.23 options expiring 15 Dec 2015
	(<i>including</i> the ⁺ securities in section 2 if applicable)	4,200,000	\$0.285 options expiring 30 June 2017
		50,000	\$0.90 options expiring 31 December 2017
		150,000	\$0.90 options expiring 31 December 2017 (vesting 30 April 2015)
		300,000	\$1.05 options expiring 31 December 2017 (vesting 30 April 2016)
		175,000	\$0.90 options expiring 31 December 2017 (vesting 30 September 2015)
		325,000	\$1.05 options expiring 31 December 2017 (vesting 30 September 2016)
		2,300,000	\$0.766 options expiring 31 December 2017
		500,000	\$0.766 options expiring 31 December 2017 (vesting 1 May 2015)
		1,000,000	\$0.90 options expiring 31 December 2017 (vesting 1 September 2015)
		1,000,000	\$1.05 options expiring 31 December 2017 (vesting 1 February 2016)
		550,000	\$0.766 options expiring 31 December 2017 (vesting 31 December 2015)
		750,000	\$0.90 options expiring 31 December 2017 (vesting 31 December 2016)
		850,000	\$1.05 options expiring 31 December 2017 (vesting 30 June 2017)
		260,000	\$1.15 options expiring 31 December 2017 (vesting 30 September 2016)
		520,000	\$1.25 options expiring 31 December 2017 (vesting 30 September 2016

⁺ See chapter 19 for defined terms.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company may pay dividends to ordinary shareholders as the Directors resolve.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non- renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their	N/A
	entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities (*tick one*)

(b)

- (a) +Securities described in Part 1
 - All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	\square	A copy of any trust deed for the additional ⁺ securities

⁺ See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities?	N/A	
	 If the additional ⁺securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of	N/A	
	another *security, clearly identify that other *security)		
47	Number and ⁺ class of all	Number N/A	+Class
42	*securities quoted on ASX (<i>including</i> the *securities in clause 38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	N J Bassett Company secretary	Date: 3 August 2015
Print name:	Neville John Bassett	

== == == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Г

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue		117,907,199	
Add the following:	Issues under an exception to rule 7.2		
 Number of fully paid ⁺ordinary securities issued in that 12 	Issue of ordinary shares on exercise of options (14/1/15)	250,000	
month period under an exception in rule 7.2	Issue of ordinary shares on exercise of options (22/1/15)	750,000	
 Number of fully paid ⁺ordinary 	Issue of ordinary shares on exercise of options (3/2/15)	100,500	
securities issued in that 12 month period with shareholder	Issue of ordinary shares on exercise of options (10/2/15)	137,500	
approval	Issue of ordinary shares on exercise of options (10/6/15)	35,000	
• Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	Issue of ordinary shares on exercise of options (26/6/15)	50,000	
Note:	Issue of ordinary shares on exercise of options (2/7/15)	4,145,000	
 Include only ordinary securities here – other classes of equity 	Issue of ordinary shares on exercise of options (7/7/15)	43,000	
securities cannot be addedInclude here (if applicable) the	Issue of ordinary shares on exercise of options (16/7/15)	102,999	
securities the subject of the Appendix 3B to which this form	Issue of ordinary shares on exercise of options (21/7/15)	1,729,101	
 is annexed It may be useful to set out issues of securities on different 	Issue of ordinary shares on exercise of options (24/7/15)	1,039,565	
dates as separate line items	Issue of ordinary shares on exercise of options (29/7/15)	190,000	
	Issue of ordinary shares on exercise of options (3/8/15)	105,407	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period		Nil	
"A"		126,585,271	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15		18,987,790
Step 3: Calculate "C", the amou that has already been used	unt of placement capacity under	rule 7.1
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that	Issue of options (30/1/2015)	500,000
12 month period <i>not counting</i> those issued:	Issue of shares (4/2/2015)	8,320,000
 Under an exception in rule 7.2 	Issue of options (12/3/2015)	2,500,000
Under rule 7.1A	Issue of options (19/5/2015)	300,000
	Issue of options (16/6/2015)	2,150,000
• With security holder approval under rule 7.1 or rule 7.4	Issue of options (29/7/2015)	780,000
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	Issue of shares on conversion of unlisted Options issued 12/3/2015 (21/7/2015)	500,000
"C"		15,050,000
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15		18,987,790
Note: number must be same as shown in Step 2		
Subtract "C"		15,050,000
Note: number must be same as shown		

Note: number must be same as shown in Step 3

> 3,937,790 [Note: this is the remaining placement capacity under rule 7.1]

Total ["A" x 0.15] – "C"

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		126,585,271
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be ch	anged
<i>Multiply</i> "A" by 0.10		12,658,527
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	lssue of shares (4/2/2015)	11,680,000
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"		11,680,000

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	12,658,527	
Note: number must be same as shown in Step 2		
Subtract "E"	11,680,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	978,527	
	Note: this is the remaining placement capacity under rule 7.1A	

Г

⁺ See chapter 19 for defined terms.